GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » Cyclically Adjusted FCF per Share

Surmodics (STU:SU6) Cyclically Adjusted FCF per Share : €0.57 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Surmodics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Surmodics's adjusted free cash flow per share for the three months ended in Jun. 2024 was €-0.196. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.57 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Surmodics's average Cyclically Adjusted FCF Growth Rate was -22.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -9.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -5.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Surmodics was 10.40% per year. The lowest was -9.00% per year. And the median was 1.90% per year.

As of today (2024-09-26), Surmodics's current stock price is €34.60. Surmodics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €0.57. Surmodics's Cyclically Adjusted Price-to-FCF of today is 60.70.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Surmodics was 77.77. The lowest was 15.32. And the median was 39.91.


Surmodics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Surmodics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cyclically Adjusted FCF per Share Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.85 0.87 0.83 0.69

Surmodics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.69 0.59 0.63 0.57

Competitive Comparison of Surmodics's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Surmodics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Surmodics's Cyclically Adjusted Price-to-FCF falls into.



Surmodics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Surmodics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.196/132.5538*132.5538
=-0.196

Current CPI (Jun. 2024) = 132.5538.

Surmodics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 0.272 100.428 0.359
201412 0.329 99.070 0.440
201503 0.082 99.621 0.109
201506 0.336 100.684 0.442
201509 0.102 100.392 0.135
201512 0.410 99.792 0.545
201603 0.184 100.470 0.243
201606 0.342 101.688 0.446
201609 0.220 101.861 0.286
201612 0.029 101.863 0.038
201703 0.069 102.862 0.089
201706 0.092 103.349 0.118
201709 0.305 104.136 0.388
201712 -0.044 104.011 -0.056
201803 1.451 105.290 1.827
201806 -0.363 106.317 -0.453
201809 0.139 106.507 0.173
201812 -0.475 105.998 -0.594
201903 0.027 107.251 0.033
201906 -0.101 108.070 -0.124
201909 0.652 108.329 0.798
201912 -0.169 108.420 -0.207
202003 0.100 108.902 0.122
202006 0.716 108.767 0.873
202009 0.017 109.815 0.021
202012 -0.396 109.897 -0.478
202103 0.923 111.754 1.095
202106 0.111 114.631 0.128
202109 -0.091 115.734 -0.104
202112 -0.498 117.630 -0.561
202203 -0.349 121.301 -0.381
202206 -0.296 125.017 -0.314
202209 -0.223 125.227 -0.236
202212 -0.795 125.222 -0.842
202303 -0.436 127.348 -0.454
202306 1.667 128.729 1.717
202309 0.033 129.860 0.034
202312 -0.618 129.419 -0.633
202403 0.399 131.776 0.401
202406 -0.196 132.554 -0.196

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Surmodics  (STU:SU6) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Surmodics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=34.60/0.57
=60.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Surmodics was 77.77. The lowest was 15.32. And the median was 39.91.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Surmodics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Surmodics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics Headlines

No Headlines